{"id":"NCT01236768","sponsor":"Agile Therapeutics","briefTitle":"Transdermal Contraceptive Delivery System (TCDS), Also Known as AG200-15 Patch Arm","officialTitle":"An Open-Label, Randomized, Phase 3 Study of the Contraceptive Efficacy and Safety of Agile Transdermal Contraceptive Delivery System in Comparison to an Oral Contraceptive (OC) Containing 150 mcg LNG and 30 mcg EE","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-10","primaryCompletion":"2011-06","completion":"2011-06","firstPosted":"2010-11-09","resultsPosted":"2017-09-15","lastUpdate":"2017-09-15"},"enrollment":407,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Contraception"],"interventions":[{"type":"DRUG","name":"AG200-15","otherNames":["Transdermal contraceptive delivery system (TCDS)"]},{"type":"DRUG","name":"Levora","otherNames":["Hormonal oral contraceptive"]}],"arms":[{"label":"AG200-15","type":"EXPERIMENTAL"},{"label":"Levora","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of the study is to evaluate the efficacy and safety of a low dose transdermal contraceptive delivery system containing ethinyl estradiol and levonorgestrel.","primaryOutcome":{"measure":"Pregnancy Reported as Pearl Index","timeFrame":"6 months","effectByArm":[{"arm":"AG200-15","deltaMin":8.19,"sd":null},{"arm":"Levora","deltaMin":6.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":5},"locations":{"siteCount":21,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":177},"commonTop":["Cervical dysplasia","Nasopharyngitis","Nausea","Upper respiratory infection","Sinusitis"]}}